Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BIOCRATES Test Kit Helps Develop First Metabolomics-Based Blood Test for Alzheimer’s

Published: Tuesday, March 18, 2014
Last Updated: Thursday, March 20, 2014
Bookmark and Share
The test is capable of predicting, with 90% accuracy, the risk of Alzheimer’s disease 2–3 years before it has actually become clinically manifest.

The findings, published in Nature Medicine, were generated using the validated AbsoluteIDQ® p180 test kit by Austrian BIOCRATES Life Sciences AG, a leading developer of innovative metabolomics solutions.

A team of researchers in Georgetown, Washington DC, and Rochester, New York, has developed the world’s first blood test capable of predicting Alzheimer’s disease. The first-of-its-kind study, recently published in Nature Medicine, used the AbsoluteIDQ® p180 test kit by BIOCRATES Life Sciences AG, a leading Austrian biotech company specialized in targeted metabolite quantification. 

Alzheimer’s disease currently affects more than 35 million individuals worldwide, and this figure is expected to increase to up to 150 million by 2050. A cure for Alzheimer’s disease is currently not available, but early detection could contribute to substantially improving the situation of affected individuals. While biomarkers have long been expected to provide important clues to the early causes of Alzheimer’s disease, current biomarkers are either invasive, time-consuming, or costly. The team around Mapstone and Federoff now discovered that a set of 10 lipids from peripheral blood predicts the development of mild cognitive impairment or Alzheimer’s disease with over 90% accuracy and 2–3 years in advance. Although it will take some time to develop test versions fit for use in doctors’ offices, the findings by Mapstone et al. are an impressive example of the power of metabolomics in diagnosis and biomarker discovery.

AbsoluteIDQ p180 provides extensive metabolic information from a single targeted assay, quantifying 186 analytes from 5 substance classes in a high-throughput manner. It features the advanced proprietary MetIDQ™ software solution, requires minute sample volumes (10 µL), and is suitable for use with a wide range of biological samples, making it an excellent choice for researchers looking for a cost-effective solution to measure endogenous metabolites under quality-controlled conditions. The AbsoluteIDQ kits by BIOCRATES have been successfully applied in many different areas, including diabetes, nephrology, sepsis, and CNS disorders, in both clinical and pharmaceutical research.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BIOCRATES Goes Spain and Turkey
Austrian diagnostic expert in personalized medicine continues to expand its European distribution network.
Thursday, May 10, 2012
BIOCRATES and Selexis Join Forces to Optimize High-yield Mammalian Cell Cultures
The agreement enables both the parties to combine their knowledge to help lower overall manufacturing costs for pharmacologically active proteins.
Tuesday, August 31, 2010
BIOCRATES Joins European Research Consortium – SysKid
The Company has joined a multi-partner European research program dedicated to improving the diagnosis and treatment of chronic kidney disease.
Thursday, April 01, 2010
BIOCRATES’ Metabolomics Expertise Provides New Insight into Functional Genomics
German researchers used Biocrates’ metabolomics expertise in research linking the genetic make-up of an individual to differences in their metabolism.
Tuesday, February 03, 2009
BIOCRATES Participates in 2.9€ Million EU Cancer Diagnostics Project
The latest framework six EU projects called COBRED will use technology platforms to find diagnostic biomarkers for two of the most common cancers, Colon and Breast Cancer.
Friday, May 11, 2007
Biocrates Raises €5 Million in Venture Financing
This investment further strengthens Biocrates’ position in the field of high content analysis and discovery of multiparametric biomarkers.
Thursday, June 29, 2006
Scientific News
New ACE-inhibiting Molecule Found in the Asparagus
Scientists have determined that sulfur-containing compounds in plants can inhibit ACE.
A Metabolic Master Switch Underlying Human Obesity
Researchers find pathway that controls metabolism by prompting fat cells to store or burn fat.
Shedding Light On Century-Old Biochemical Mystery
Yale scientists have used magnetic resonance measurements to show how glucose is metabolized in yeast to answer the puzzle of the “Warburg Effect.”
PTR-MS Breath Test Shows Potential for Detecting Liver Disease
Researchers at the University of Birmingham have published results that suggest a non-invasive breath test for liver disease using an IONICON PTR-MS.
Metabolon and BCM Show Metabolomics May Play Key Role in Precision Medicine
Metabolon’s technology enhances understanding of genetic data and improves health assessment in newly published study.
Newly Discovered Cells Restore Liver Damage in Mice Without Cancer Risk
The liver is unique among organs in its ability to regenerate after being damaged. Exactly how it repairs itself remained a mystery until recently, when researchers supported by the NIH discovered a type of cell in mice essential to the process
Study Finds Cutting Dietary Fat Reduces Body Fat More than Cutting Carbs
In a recent study, restricting dietary fat led to body fat loss at a rate 68 percent higher than cutting the same number of carbohydrate calories when adults with obesity ate strictly controlled diets.
Inappropriate Medical Food Use in Managing Patients with a Type of Metabolic Disorder
Researchers have proposed that there is a need for more rigorous clinical study of dietary management practices for patients with IEMs, including any associated long-term side effects, which may in turn result in the need to reformulate some medical foods.
Medical Researchers a Step Closer to Developing Anti-Obesity Pill
A weight loss pill could soon be possible thanks to the work of Deakin University medical researchers.
Engineered Bacterium Produces Important Industrial Chemical
A Korean research team has reported the production of 1,3-diaminopropane via fermentation of an engineered bacterium.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!